Bloodborne biomolecular markers in prostate cancer development and progression

被引：39

作者：

Bok, RA ^{[1
]}

Small, EJ

机构：

[1] Univ Calif San Francisco, Dept Med, Urol Oncol Program, Ctr Comprehens Canc, San Francisco, CA 94143 USA

[2] Univ Calif San Francisco, Dept Urol, Urol Oncol Program, Ctr Comprehens Canc, San Francisco, CA 94143 USA

来源：

NATURE REVIEWS CANCER | 2002年 / 2卷 / 12期

关键词：

D O I：

10.1038/nrc951

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Prostate cancer is notoriously difficult to treat, which makes its early detection a priority. Biomarkers have been used to diagnose and monitor prostate cancer for more than 50 years, and the discovery of the serum marker prostate-specific antigen (PSA) significantly altered the detection and management of prostate cancer. But imperfect correlation with cancer hinders the usefulness of PSA. The elucidation and validation of new biological markers of prostate cancer should aid detection, and improve the application of the available therapeutics.

引用

收藏

页码：918 / 926

页数：9

相关论文

共 92 条

[81] A SENSITIVE ENZYME-IMMUNOASSAY FOR HUMAN BASIC FIBROBLAST GROWTH-FACTOR [J].

WATANABE, H ;

HORI, A ;

SENO, M ;

KOZAI, Y ;

IGARASHI, K ;

ICHIMORI, Y ;

KONDO, K .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 175 (01) :229-235

[82]

Webber MM, 1995, CLIN CANCER RES, V1, P1089

[83] Micrometastases of bone marrow in localized prostate cancer:: Correlation with established risk factors [J].

Weckermann, D ;

Müller, P ;

Wawroschek, F ;

Krawczak, G ;

Riethmüller, G ;

Schlimok, G .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) :3438-3443

[84]

WEIDNER N, 1993, AM J PATHOL, V143, P401

[85] Neuroendocrine differentiation in prostate cancer: Enhanced prediction of progression after radical prostatectomy [J].

Weinstein, MH ;

Partin, AW ;

Veltri, RW ;

Epstein, JI .

HUMAN PATHOLOGY, 1996, 27 (07) :683-687

[86] ACID-PHOSPHATASE - ITS INFLUENCE ON THE MANAGEMENT OF CARCINOMA OF THE PROSTATE [J].

WHITESEL, JA ;

DONOHUE, RE ;

MANI, JH ;

MOHR, S ;

SCANAVINO, DJ ;

AUGSPURGER, RR ;

BIBER, RJ ;

FAUVER, HE ;

WETTLAUFER, JN ;

PFISTER, RR .

JOURNAL OF UROLOGY, 1984, 131 (01) :70-72

[87] Pretreatment levels of urinary deoxypyridinoline as a potential marker in patients with prostate cancer with or without bone metastasis [J].

Wymenga, LFA ;

Groenier, K ;

Schuurman, J ;

Boomsma, JHB ;

Elferink, RO ;

Mensink, HJA .

BJU INTERNATIONAL, 2001, 88 (03) :231-235

[88] METABOLIC EPIDEMIOLOGY OF PROSTATIC-CANCER [J].

WYNDER, EL ;

LAAKSO, K ;

SOTARAUTA, M ;

ROSE, DP .

PROSTATE, 1984, 5 (01) :47-53

[89]

Yao KL, 1997, CANC TREAT, V88, P77

[90] Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma [J].

Yoshikawa, T ;

Tsuburaya, A ;

Kobayashi, O ;

Sairenji, M ;

Motohashi, H ;

Yanoma, S ;

Noguchi, Y .

CANCER LETTERS, 2000, 153 (1-2) :7-12

← 1 2 3 4 5 6 7 8 9 10 →